DOI QR코드

DOI QR Code

Radiotherapy Alone is Associated with Improved Outcomes Over Surgery in the Management of Solitary Plasmacytoma

  • Li, Qi-Wen (Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center) ;
  • Niu, Shao-Qing (Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center) ;
  • Wang, Han-Yu (Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center) ;
  • Wen, Ge (Department of Radiation Oncology, The Third Affiliated Hospital of Guangzhou Medical University) ;
  • Li, Yi-Yang (Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center) ;
  • Xia, Yun-Fei (Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center) ;
  • Zhang, Yu-Jing (Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center)
  • Published : 2015.05.18

Abstract

Background: A moderate dose of radiation is the recommended treatment for solitary plasmacytoma (SP), but there is controversy over the role of surgery. Our study aimed at comparing different treatment modalities in the management of SP. Materials and Methods: Data from 38 consecutive patients with solitary plasmacytoma, including 16 with bone plasmacytoma and 22 with extramedullary plasmacytoma, were retrospectively reviewed. 15 patients received radiotherapy alone; 11 received surgery alone, and 12 received both. The median radiation dose was 50Gy. All operations were performed as radical resections. Local progression-free survival (LPFS), multiple myeloma-free survival (MMFS), progression-free survival (PFS) and overall survival (OS) were calculated and outcomes of different therapies were compared. Results: The median follow-up time was 55 months. 5-year LPFS, MMFS, PFS and OS were 87.0%, 80.9%, 69.8% and 87.4%, respectively. Univariate analysis revealed, compared with surgery alone, radiotherapy alone was associated with significantly higher 5-year LPFS (100% vs 69.3%, p=0.016), MMFS (100% vs 51.4%, p=0.006), PFS (100% vs 33.7%, p=0.0004) and OS (100% vs 70%, p=0.041). Conclusions: Radiotherapy alone can be considered as a more effective treatment for SP over surgery. Whether a combination of radiotherapy and surgery improves outcomes requires further study.

Keywords

Solitary plasmacytoma;radiotherapy;prognostic factors;multiple myeloma

References

  1. Alexiou C, Kau RJ, Dietzfelbinger H, et al (1999). Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts. Cancer, 85, 2305-14. https://doi.org/10.1002/(SICI)1097-0142(19990601)85:11<2305::AID-CNCR2>3.0.CO;2-3
  2. Bachar G, Goldstein D, Brown D, et al (2008). Solitary extramedullary plasmacytoma of the head and neck-long-term outcome analysis of 68 cases. Head Neck, 30, 1012-9. https://doi.org/10.1002/hed.20821
  3. Bataille R, Sany J (1981). Solitary myeloma: clinical and prognostic features of a review of 114 cases. Cancer, 48, 845-51. https://doi.org/10.1002/1097-0142(19810801)48:3<845::AID-CNCR2820480330>3.0.CO;2-E
  4. Batsakis JG (1983). Pathology consultation. Plasma cell tumors of the head and neck. Ann Otol Rhinol Laryngol, 92, 311-3. https://doi.org/10.1177/000348948309200320
  5. Chak LY, Cox RS, Bostwick DG, Hoppe RT (1987). Solitary plasmacytoma of bone: treatment, progression, and survival. J Clin Oncol, 5, 1811-5.
  6. Creach KM, Foote RL, Neben-Wittich MA, Kyle RA (2009). Radiotherapy for extramedullary plasmacytoma of the head and neck. Int J Radiat Oncol Biol Phys, 73, 789-94. https://doi.org/10.1016/j.ijrobp.2008.04.077
  7. Dimopoulos MA, Hamilos G (2002). Solitary bone plasmacytoma and extramedullary plasmacytoma. Curr Treat Options Oncol, 3, 255-9. https://doi.org/10.1007/s11864-002-0015-2
  8. Frassica DA, Frassica FJ, Schray MF, Sim FH, Kyle RA (1989). Solitary plasmacytoma of bone: Mayo Clinic experience. Int J Radiat Oncol Biol Phys, 16, 43-8. https://doi.org/10.1016/0360-3016(89)90008-4
  9. Guo SQ, Zhang L, Wang YF, et al (2013). Prognostic factors associated with solitary plasmacytoma. Onco Targets Ther, 14, 1659-66.
  10. Gerry D, Lentsch EJ (2013). Epidemiologic evidence of superior outcomes for extramedullary plasmacytoma of the head and neck. Otolaryngol Head Neck Surg, 148, 974-81. https://doi.org/10.1177/0194599813481334
  11. Hill QA, Rawstron AC, de Tute RM, Owen RG (2014). Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis. Blood, 124, 1296-9. https://doi.org/10.1182/blood-2014-04-566521
  12. Holland J, Trenkner DA, Wasserman TH, Fineberg B (1992). Plasmacytoma. Treatment results and conversion to myeloma. Cancer, 69, 1513-7. https://doi.org/10.1002/1097-0142(19920315)69:6<1513::AID-CNCR2820690633>3.0.CO;2-X
  13. Huang WD, Feng DP, Xiao JR, et al (2010). Surgical intervention and radiotherapy outcome of solitary plasmacytoma of cervical spine. Zhonghua Wai Ke Za Zhi, 48, 697-701.
  14. Katodritou E, Terpos E, Symeonidis AS, et al (2014). Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients. Am J Hematol, 89, 803-8. https://doi.org/10.1002/ajh.23745
  15. Khan MM, Mori M, Sakauchi F, et al (2006). Risk factors for multiple myeloma: evidence from the Japan Collaborative Cohort (JACC) study. Asian Pac J Cancer Prev, 7, 575-81.
  16. Kilciksiz S, Celik OK, Pak Y, et al (2008). Clinical and prognostic features of plasmacytomas: a multicenter study of Turkish Oncology Group-Sarcoma Working Party. Am J Hematol, 83, 702-7. https://doi.org/10.1002/ajh.21211
  17. Knowling MA, Harwood AR, Bergsagel DE (1983). Comparison of extramedullary plasmacytomas with solitary and multiple plasma cell tumors of bone. J Clin Oncol, 1, 255-62.
  18. Kocak E, Ballerini G, Zouhair A, Ozsahin M (2010). Radiation therapy for the solitary plasmacytoma. Turk J Hematol, 27, 57-61. https://doi.org/10.5152/tjh.2010.01
  19. Kotner LM, Wang CC (1972). Plasmacytoma of the upper air and food passages. Cancer, 30, 414-8. https://doi.org/10.1002/1097-0142(197208)30:2<414::AID-CNCR2820300217>3.0.CO;2-Z
  20. Liebross RH, Ha CS, Cox JD, et al (1998). Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy. Int J Radiat Oncol Biol Phys, 41, 1063-7. https://doi.org/10.1016/S0360-3016(98)00186-2
  21. Mayr NA, Wen BC, Hussey DH, et al (1990). The role of radiation therapy in the treatment of solitary plasmacytomas. Radiother Oncol, 17, 293-303. https://doi.org/10.1016/0167-8140(90)90003-F
  22. Mendenhall CM, Thar TL, Million RR (1980). Solitary plasmacytoma of bone and soft tissue. Int J Radiat Oncol Biol Phys, 6, 1497-501. https://doi.org/10.1016/0360-3016(80)90006-1
  23. Mendenhall WM, Mendenhall CM, Mendenhall NP (2003). Solitary plasmacytoma of bone and soft tissues. Am J Otolaryngol, 24, 395-9. https://doi.org/10.1016/S0196-0709(03)00092-9
  24. Michalaki VJ, Hall J, Henk JM, Nutting CM, Harrington KJ (2003). Definitive radiotherapy for extramedullary plasmacytomas of the head and neck. Br J Radiol, 76, 738-41. https://doi.org/10.1259/bjr/54563070
  25. Ozsahin M, Tsang RW, Poortmans P, et al (2006). Outcomes and patterns of failure in solitary plasmacytoma: a multicenter rare cancer network study of 258 patients. Int J Radiat Oncol Biol Phys, 64, 210-7. https://doi.org/10.1016/j.ijrobp.2005.06.039
  26. Paiva B, Chandia M, Vidriales MB, et al (2014). Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma. Blood, 124, 1300-3. https://doi.org/10.1182/blood-2014-04-567909
  27. Reed V, Shah J, Medeiros LJ, et al (2011). Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy. Cancer, 117, 4468-74. https://doi.org/10.1002/cncr.26031
  28. Sasaki R, Yasuda K, Abe E, et al (2012). Multi-institutional analysis of solitary extramedullary plasmacytoma of the head and neck treated with curative radiotherapy. Int J Radiat Oncol Biol Phys, 82, 626-34. https://doi.org/10.1016/j.ijrobp.2010.11.037
  29. Soutar R, Lucraft H, Jackson G, et al (2004). Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Br J Haematol, 124, 717-26. https://doi.org/10.1111/j.1365-2141.2004.04834.x
  30. Strojan P, Soba E, Lamovec J, Munda A (2002). Extramedullary plasmacytoma: clinical and histopathologic study. Int J Radiat Oncol Biol Phys, 53, 692-701. https://doi.org/10.1016/S0360-3016(02)02780-3
  31. Suh YG, Suh CO, Kim JS, et al (2012). Radiotherapy for solitary plasmacytoma of bone and soft tissue: outcomes and prognostic factors. Ann Hematol, 91, 1785-93. https://doi.org/10.1007/s00277-012-1510-6
  32. Sundaresan N, Steinberger AA, Moore F, et al (1996). Indications and results of combined anterior-posterior approaches for spine tumor surgery. J Neurosurg, 85, 438-46. https://doi.org/10.3171/jns.1996.85.3.0438
  33. Tournier-Rangeard L, Lapeyre M, Graff-Caillaud P, et al (2006). Radiotherapy for solitary extramedullary plasmacytoma in the head-and-neck region: A dose greater than 45 Gy to the target volume improves the local control. Int J Radiat Oncol Biol Phys, 64, 1013-7. https://doi.org/10.1016/j.ijrobp.2005.09.019
  34. Tsang RW, Gospodarowicz MK, Pintilie M, et al (2001). Solitary plasmacytoma treated with radiotherapy: impact of tumor size on outcome. Int J Radiat Oncol Biol Phys, 50, 113-20. https://doi.org/10.1016/S0360-3016(00)01572-8

Cited by

  1. Solitary plasmacytoma: population-based analysis of survival trends and effect of various treatment modalities in the USA vol.17, pp.1, 2017, https://doi.org/10.1186/s12885-016-3015-5
  2. A Case of Extramedullary Plasmacytoma Presenting as a Large Jugular Foramen Tumor vol.60, pp.5, 2017, https://doi.org/10.3342/kjorl-hns.2016.16145
  3. Place of Sterotactic Radiotherapy in Treatment of Extramedullary Plasmocytoma pp.1049-2275, 2018, https://doi.org/10.1097/SCS.0000000000004844
  4. Testicular plasmacytoma: unique location or circumstantial presentation? vol.59, pp.8, 2018, https://doi.org/10.1080/10428194.2017.1421763